Home › TESARO and Merck to Collaborate on a Combination Study of Niraparib and KEYTRUDA (pembrolizumab)
 

Keywords :   


TESARO and Merck to Collaborate on a Combination Study of Niraparib and KEYTRUDA (pembrolizumab)

2015-05-30 20:00:20| Merck.com - Product News

Dateline City: WALTHAM, Mass., and KENILWORTH, N.J. Clinical Trial Will Evaluate TESAROs PARP Inhibitor with Mercks Anti-PD-1 Therapy in Patients with Breast and Ovarian Cancers WALTHAM, Mass., and KENILWORTH, N.J., May 30, 2015 TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced a collaboration to evaluate the combination of TESAROs niraparib plus Mercks anti-PD1 therapy, KEYTRUDA (pembrolizumab), in a Phase 1/2 clinical trial. Language: English read more

Tags: study combination collaborate merck

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
06.07Atlantic Tropical Weather Outlook
06.07Tropical Storm Beryl Public Advisory Number 30A
06.07Summary for Tropical Storm Beryl (AT2/AL022024)
06.07Eastern North Pacific Tropical Weather Outlook
06.07Tropical Storm Beryl Potential Storm Surge Flooding Map
06.07Tropical Storm Beryl Probabilistic Storm Surge Graphics
06.07Tropical Storm Beryl Forecast Discussion Number 30
06.07Tropical Storm Beryl Graphics
More »